Most Read Articles
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.

Poor sleep quality predicts obesity

11 Jul 2020

Among middle-aged and older adults, sleeping poorly is related to general and abdominal obesity, short sleep duration to both sarcopaenic and general obesity, and depression to sarcopaenia, as suggested in a study.

The analysis included 304 individuals (mean age, 72.04 years; 83.88 percent female). Mean sleep duration was 6.73 hours, and the hours were short (<6) in 63 participants, normal (6–8) in 208, and long (>8) in 33.

Researchers measured depression using the Hospital Anxiety and Depression Scale. They also assessed body mass index, waist circumference, skeletal muscle mass index (bioelectrical impedance analysis), and handgrip strength. Based on these data, 23.68 percent of the population had sarcopaenia, 38.82 percent had general obesity, 73.68 percent had abdominal obesity, and 5.59 percent had sarcopaenic obesity (SO).

On multivariate logistic regressions, sarcopaenia was associated with depression only (odds ratio [OR], 1.10), whereas general obesity was linked to poorer sleep quality (OR, 1.06) and short sleep duration (OR, 2.63), greater fatigue (OR, 1.03), and low physical activity (PA) levels (OR, 2.25).

Independent predictors of abdominal obesity included poor sleep latency (OR, 1.43), fatigue (OR, 1.03), low PA levels (OR, 2.48), older age (OR, 1.05), and female sex (OR, 3.10). Finally, SO was associated with short sleep duration (OR, 5.25), greater fatigue (OR, 1.04), low PA levels (OR, 4.039), and male sex (OR, 0.21).

The present data highlight the importance of improving sleep duration and quality, as well as addressing depression, in the prevention of sarcopaenia, obesity, and SO.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.